This is a prospective registry study to surveil early liver injuries caused by Xianlin Gubao Capsule (XLGB Capsule) through a non-intervention observational way. And attempt to establish a predictive model to screen susceptibilities to XLGB Capsule.
The primary objectives of this study include: (i) The detection of patients with serum liver biochemistry abnormalities within 8 weeks after intake of XLGB Capsule; (ii) The record of overall individuals with demographics, underlying diseases, physical status, medication information, clinical laboratory index, and so on; (iii) The specimen collection of surveiled individuals. (iv) The attempt to establish a predictive model to screen susceptibilities to XLGB Capsule.
Study Type
OBSERVATIONAL
Enrollment
1,000
302 Military Hospital
Beijing, Beijing Municipality, China
The detection of patients with serum liver biochemistry abnormalities within 8 weeks after intake of XLGB Capsule.
The detection of patients with serum liver biochemistry abnormalities within 8 weeks after intake of XLGB Capsule.
Time frame: participants will be followed duration intake of XLGB Capsule, an expected average within 8 weeks
Clinical features of early liver injuries caused by XLGB Capsule assessed by serum parameters of liver function.
Clinical features of early liver injuries caused by XLGB Capsule assessed by serum parameters of liver function.
Time frame: participants will be followed duration intake of XLGB Capsule, an expected average of 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.